Details for New Drug Application (NDA): 020227
NDA 020227 describes NORMIFLO, which is a drug marketed by Pharmacia And Upjohn and is included in one NDA. Additional details are available on the NORMIFLO profile page.
The generic ingredient in NORMIFLO is ardeparin sodium. There is one drug master file entry for this compound. Additional details are available on the ardeparin sodium profile page.
The generic ingredient in NORMIFLO is ardeparin sodium. There is one drug master file entry for this compound. Additional details are available on the ardeparin sodium profile page.
Summary for 020227
| Tradename: | NORMIFLO |
| Applicant: | Pharmacia And Upjohn |
| Ingredient: | ardeparin sodium |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 10,000 UNITS/0.5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | May 23, 1997 | TE: | RLD: | Yes | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 5,000 UNITS/0.5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | May 23, 1997 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
